Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML October 1, 2012

D., Andrew McDonald, Ph.D.


Summary

ARIAD Pharmaceuticals (ARIA) is a clinical stage company focused on the development and commercialization of therapeutics primarily to address mutated or resistant forms of cancer.


The Company anticipates receiving its first FDA approval by Q1 2013 for its lead agent, ponatinib, as a second line therapeutic for Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ALL) patients. Ponatinib has shown significant efficacy against resistant forms of leukemia, including cancer cells with the T315I mutation, for which no therapeutic options exist today.


seekingalpha.com/article/897141